Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

ProMune Phase III lung cancer trial plans outlined in Coley's recent IPO prospectus filing. With licensee Pfizer funding ProMune for cancer applications, the bulk of the initial public offering proceeds will go toward expanding Coley's early-phase infectious disease program.

You may also be interested in...



Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program

$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.

Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program

$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.

Coley Seeks HCV Partner For Actilon

Firm suspends independent development of the hepatitis C agent in hopes of finding a partner with resources and expertise to share the risk.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel